Windtree Therapeutics Soars 76.71% on Patent Win

On July 14, 2025, Windtree Therapeutics, Inc. Common Stock (WINT) surged by 76.71% in pre-market trading, marking a significant rise in its stock price.

Windtree Therapeutics, Inc. is anticipated to release its earnings report on August 18, 2025. This upcoming earnings date is derived from an algorithm based on historical data and market trends.

The company has received a consensus rating of Hold, with an average rating score of 2.00. This rating is based on one hold rating and no buy or sell ratings, indicating a cautious outlook from analysts.

Windtree Therapeutics is currently conducting a global trial at sites in the United States, Europe, and Latin America. The trial is designed as a placebo-controlled and double-blinded study, aiming to evaluate the efficacy and safety of its therapeutic products.

Recently, Windtree Therapeutics, Inc. announced that it was issued an important patent, which has contributed to the surge in its stock price. This patent is expected to strengthen the company's intellectual property portfolio and enhance its competitive position in the market.